Opportunities and challenges in the era of molecularly targeted agents and radiation therapy

Steven H. Lin, Thomas J. George, Edgar Ben-Josef, Jeffrey Bradley, Kevin S. Choe, Martin J. Edelman, Chandan Guha, Sunil Krishnan, Theodore S. Lawrence, Quynh Thu Le, Bo Lu, Minesh Mehta, David Peereboom, Jann Sarkaria, Jinsil Seong, Dian Wang, Meng X. Welliver, C. Norman Coleman, Bhadrasain Vikram, Stephen YooChristine H. Chung

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.

Original languageEnglish
Pages (from-to)686-693
Number of pages8
JournalJournal of the National Cancer Institute
Volume105
Issue number10
DOIs
Publication statusPublished - 2013 May 15

Fingerprint

Radiotherapy
Neoplasms
Education
Radiation Oncology
National Cancer Institute (U.S.)
Drug Discovery
Therapeutics
Biomarkers
Technology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lin, S. H., George, T. J., Ben-Josef, E., Bradley, J., Choe, K. S., Edelman, M. J., ... Chung, C. H. (2013). Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. Journal of the National Cancer Institute, 105(10), 686-693. https://doi.org/10.1093/jnci/djt055
Lin, Steven H. ; George, Thomas J. ; Ben-Josef, Edgar ; Bradley, Jeffrey ; Choe, Kevin S. ; Edelman, Martin J. ; Guha, Chandan ; Krishnan, Sunil ; Lawrence, Theodore S. ; Le, Quynh Thu ; Lu, Bo ; Mehta, Minesh ; Peereboom, David ; Sarkaria, Jann ; Seong, Jinsil ; Wang, Dian ; Welliver, Meng X. ; Coleman, C. Norman ; Vikram, Bhadrasain ; Yoo, Stephen ; Chung, Christine H. / Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. In: Journal of the National Cancer Institute. 2013 ; Vol. 105, No. 10. pp. 686-693.
@article{1793302c207a40fd8cc3b0c41ae52482,
title = "Opportunities and challenges in the era of molecularly targeted agents and radiation therapy",
abstract = "The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.",
author = "Lin, {Steven H.} and George, {Thomas J.} and Edgar Ben-Josef and Jeffrey Bradley and Choe, {Kevin S.} and Edelman, {Martin J.} and Chandan Guha and Sunil Krishnan and Lawrence, {Theodore S.} and Le, {Quynh Thu} and Bo Lu and Minesh Mehta and David Peereboom and Jann Sarkaria and Jinsil Seong and Dian Wang and Welliver, {Meng X.} and Coleman, {C. Norman} and Bhadrasain Vikram and Stephen Yoo and Chung, {Christine H.}",
year = "2013",
month = "5",
day = "15",
doi = "10.1093/jnci/djt055",
language = "English",
volume = "105",
pages = "686--693",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

Lin, SH, George, TJ, Ben-Josef, E, Bradley, J, Choe, KS, Edelman, MJ, Guha, C, Krishnan, S, Lawrence, TS, Le, QT, Lu, B, Mehta, M, Peereboom, D, Sarkaria, J, Seong, J, Wang, D, Welliver, MX, Coleman, CN, Vikram, B, Yoo, S & Chung, CH 2013, 'Opportunities and challenges in the era of molecularly targeted agents and radiation therapy', Journal of the National Cancer Institute, vol. 105, no. 10, pp. 686-693. https://doi.org/10.1093/jnci/djt055

Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. / Lin, Steven H.; George, Thomas J.; Ben-Josef, Edgar; Bradley, Jeffrey; Choe, Kevin S.; Edelman, Martin J.; Guha, Chandan; Krishnan, Sunil; Lawrence, Theodore S.; Le, Quynh Thu; Lu, Bo; Mehta, Minesh; Peereboom, David; Sarkaria, Jann; Seong, Jinsil; Wang, Dian; Welliver, Meng X.; Coleman, C. Norman; Vikram, Bhadrasain; Yoo, Stephen; Chung, Christine H.

In: Journal of the National Cancer Institute, Vol. 105, No. 10, 15.05.2013, p. 686-693.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Opportunities and challenges in the era of molecularly targeted agents and radiation therapy

AU - Lin, Steven H.

AU - George, Thomas J.

AU - Ben-Josef, Edgar

AU - Bradley, Jeffrey

AU - Choe, Kevin S.

AU - Edelman, Martin J.

AU - Guha, Chandan

AU - Krishnan, Sunil

AU - Lawrence, Theodore S.

AU - Le, Quynh Thu

AU - Lu, Bo

AU - Mehta, Minesh

AU - Peereboom, David

AU - Sarkaria, Jann

AU - Seong, Jinsil

AU - Wang, Dian

AU - Welliver, Meng X.

AU - Coleman, C. Norman

AU - Vikram, Bhadrasain

AU - Yoo, Stephen

AU - Chung, Christine H.

PY - 2013/5/15

Y1 - 2013/5/15

N2 - The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.

AB - The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=84877992706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877992706&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt055

DO - 10.1093/jnci/djt055

M3 - Review article

C2 - 23503600

AN - SCOPUS:84877992706

VL - 105

SP - 686

EP - 693

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -